<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016729</url>
  </required_header>
  <id_info>
    <org_study_id>20120234</org_study_id>
    <nct_id>NCT02016729</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 Alone and in Combination With Trametinib in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute
      myeloid leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2014</start_date>
  <completion_date type="Actual">July 31, 2017</completion_date>
  <primary_completion_date type="Actual">April 19, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of AMG 232</measure>
    <time_frame>36 months</time_frame>
    <description>To evaluate the safety and tolerability of AMG 232 by reviewing clinically significant or â‰¥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the pharmacokinetics of AMG 232 alone and in combination with trametinib when administered orally.</measure>
    <time_frame>36 months</time_frame>
    <description>PK parameters will include, but are not limited to, area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose of AMG 232 alone and in combination with trametinib, if possible.</measure>
    <time_frame>36 months</time_frame>
    <description>The MTD is defined at the highest dose level with an observed incidence of dose limiting toxicity in &lt; 33% of subjects enrolled in a cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Response</measure>
    <time_frame>36 months</time_frame>
    <description>Complete response (CR), complete response with incomplete recovery (CRi), and duration response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Advanced Malignancy</condition>
  <condition>Cancer</condition>
  <condition>Oncology</condition>
  <condition>Oncology Patients</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>AMG 232</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 232 is an anti-cancer agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 232 &amp; Trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 232 and Trametinib are anti cancer agents</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 232</intervention_name>
    <description>Given an an oral tablet in escalating doses.</description>
    <arm_group_label>AMG 232</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib is an oral tablet given in a fixed dose.</description>
    <arm_group_label>AMG 232</arm_group_label>
    <arm_group_label>AMG 232 &amp; Trametinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women &gt; 18 years old

          -  Pathologically-documented, definitively-diagnosed AML that is relapsed or refractory
             to standard treatment, for which no standard therapy is available or the subject
             refuses standard therapy

          -  Ability to take oral medications and willing to record daily adherance to
             investigational product

          -  Adequate hematological, renal, hepatic, and coagulation laboratory assessments

        Exclusion Criteria:

          -  Active infection requiring intravenous (IV) antibiotics

          -  Prior participation in an investigational study (procedure or device) within 21 days
             of study day 1

          -  Major surgery within 28 days of study day 1

          -  Anti-tumor therapy within 14 days of study day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

